Short Interest in Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Grows By 11,975.0%

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 48,300 shares, a growth of 11,975.0% from the September 30th total of 400 shares. Based on an average trading volume of 1,450,400 shares, the days-to-cover ratio is presently 0.0 days.

Oncotelic Therapeutics Price Performance

OTLC opened at $0.04 on Friday. Oncotelic Therapeutics has a fifty-two week low of $0.02 and a fifty-two week high of $0.05. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.01 and a quick ratio of 0.01. The company’s 50 day moving average price is $0.02 and its two-hundred day moving average price is $0.03.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.